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Emerging paradigms of integrin ligand binding and activation. Adhe-
sion of cells to each other or to the extracellular matrix provides essential
signals that regulate many cellular functions including cell migration,
proliferation, differentiation and apoptosis. The integrin superfamily
orchestrates many of these complex adhesive events through regulated
interactions with a large variety of ligands. Crystallization of some ligands
and of a ligand-binding integrin domain, reviewed here, together with
extensive mutagenesis studies are beginning to shed light on the inner
workings of these receptors.
A common feature in several forms of glomerulonephritis,
interstitial nephritides and allograft rejection is the accumulation
of leukocytes in the extravascular interstitium, where they partic-
ipate in tissue injury, often leading to organ failure. Many studies
have established an essential role for integrins, which are het-
erodimeric surface adhesion receptors, in the cell-cell and cell-
matrix interactions involved in leukocyte extravasation, and in the
variety of functions mediated in tissues by resident or migrating
cells [1, 2]. Integrins also participate in many pathological pro-
cesses such as uncontrolled inflammation [31, thrombosis [4],
tumor growth and metastasis [5]. Anti-integrin monoclonal anti-
bodies (mAbs) have been effective therapeutic agents for the
treatment of thrombosis in humans [6], and their anti-inflamma-
tory and anti-rejection potential have been shown in several
animal models (reviewed elsewhere in this volume). The eventual
development of nonimmunogenic and selective therapeutic agents
will depend on understanding how integrins interact with their
respective ligands. Here, we review emerging paradigms of inte-
grin-ligand interactions.
Primary structure of integirns
The 22 cloned integrin heterodimers are assembled from 16 a
and eight /3 subunits (Table 1). Each of the a subunits (—1000 aa)
consists of a short C-terminal cytoplasmic tail, a single membrane-
spanning region and a large extracellular domain (Fig. 1). This
ectodomain contains seven tandem repeats, each comprised of
—60 aa, three or four of which have EF-hand-like divalent cation
binding sites. In seven a subunits (a1, a2, a0, CD11a-d), an extra
A-type domain (called A- or I-domain) is inserted between the
second and third repeats. These A-domain integrins contain three
EF-like motifs. a3, a5, a6, a7, a8, a1 and a contain four EF-like
motifs and a disulfide-linked cleavage site near the transmem-
brane region. a4 and a9 each contains three EF-like motifs but
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lack the C-terminal cleavage site, with a4 (but not a9) containing
a non-disulfide linked cleavage site in the middle of the chain.
Alternative-splicing in the cytoplasmic tails or extracellular region
of some integrins has been described [reviewed in 7].
Each of the eight /3 subunits (—750 aa) spans the membrane
once, and contains a short cytoplasmic tail, with the exception of
/3, where the cytoplasmic domain is extended by inclusion of four
fibronectin type III repeats, and two alternatively spliced sites.
The large extracellular region contains a putative A-like domain
([8], see below), and a characteristic C-terminal cysteine-rich
motif repeated four times (Fig. 1). Alternative splicing also occurs
in the cytoplasmic tails of the 13 and 133 subunits [reviewed in 7].
Electron microscopy (EM) of several integrin heterodimers [4, 9,
101 reveals a mushroom-like head comprised of the two N-
terminal halves of the a and /3 subunits and two flexible tails, each
made up of the remaining C-terminal portion of each subunit.
Integrin activation
Inactive and active receptor conformations
In circulating leukocytes, as in platelets, integrins normally exist
in a low affinity or inactive state [11—14]. This allows these cells to
circulate without improperly adhering to each other or to the
vascular endothelium. Engagement of several types of receptors
(such as chemokine, chemoattractant and antigen receptors),
causes rapid switching of integrins from the low to a high affinity
or active state (kDa —4 to 40 met [12—161) by an energy-dependent
process called 'inside-out' signaling. Ligand-bound integrins can
then transmit signals to the cell interior (outside-in signaling)
leading to changes in intracellular pH, calcium fluxes, tyrosine
phosphoiylation and organization of the cytoskeleton [17, 18].
Although switching to the high affinity state is sufficient for ligand
binding, stable cell adhesion to immobilized ligands requires
postoccupancy integrin-cytoskeleton interactions [19—22]. Affinity
switching of integrins is usually reversible, permitting cells to
undergo the adhesion—dc-adhesion cycles necessary for such
functions as cell migration, phagocytosis and target cell killing.
Activation of integrins can also be induced by the binding of
certain 'activating' mAbs [23—25] or by the divalent cation man-
ganese [26—29]. Activation in these instances does not require
metabolic energy, and although nonphysiologic, these reagents
have been invaluable in understanding the mechanics of integrin
activation by physiologic stimuli.
Integrin recycling between the inactive and active states is
associated with conformational changes in the exoplasmic do-
mains of these receptors. Biophysical, biochemical and immuno-
logical probes have been utilized to detect these structural
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Table 1. Mammalian integrins and their extracellular ligands
Extracellular ligands
Laminin, collagens 1, IV, VI
Collagnens I-TV, Laminin, vitronectin, Tenascin
(cytotactin); 03131; pathogens (Echovirus I).
Motif: DGEA
Epiligrin (kalinin), fibronectin, laminin, collagen
I, entactin, 02131, 0313; pathogens (Invasin
from Yersinia spp.). Motif: RGD
VCAM-1 (CD106), Fibronectin, 04 subunit",
pathogens (Invasin from Yersinia spp.). Motif:
LDVh (consensus: L/I-D/E-S/T/V-P/S) (e.g.
IDSP, LDV)
Fibronectin, denatured collagen, Li adhesion
molecule"; pathogens (Invasin from Yersinia
spp.). Motif: RGD
Epiligrin, laminin; pathogens (Invasin from
Yersinia spp.)
Laminin
Fibronectin, tenascin, Vitronectin"
Tenascin
Fibronectin, vitronectin; Motif: RGD
ICAM-1, -2, -3 (CD54, 102, 50); Landsteiner-
Wiener (LW) blood group glycroprotein";
pathogens (H. Capsulatum). Motif: LDV (e.g.
GIETP, ALETSL, QIDSPL)
ICAM-1, -2, -3 (CD54, 102, 50), iC3b,
fibrinogen, factor X, lipopolysaccarides
(LPS), carbohydrates", heparin',
Haptoglobin', CD23, kininogen", denatured
proteins; Landsteiner-Wiener (LW) blood
group glycoprotein"; pathogens (neutrophil
inhibitory factor from Ancylostoma C.',
filamentous hemagglutinin from Bordetella
pertussis), gp63 from Leishmania D., H.
Capsulatum, WI-I antigen from Blastomyces
dermatididistm
iC3b, fibrinogen, CD23', LPS", pathogens (H.
Capsulatum)
ICAM-3 (CD5O)°
Fibronectin, fibrinogen, von Willebrand factor
(vWF), vitronectin, thrombospondin,
collagens, denatured collagen, PECAM-i
(CD31)P; pathogens (Disintegrins, Bortelia
burgdoiferi). Motifs: RGD, KQAGDV
Fibronectin, fibrinogen, vitronectin, vWF,
thrombospondin, osteopontin, tenascin,
denatured collagen; Li adhesion molecule'1,
gelatinase Ar; pathogens (HIV Tat protein,
disintegrins, penton base protein of
adenovirus type 2'). Motif: RGD
Laminin
Fibronectin, vitronectin; pathogens (HIV Tat
protein, penton base protein of adenovirus
type 2). Motif: RGD
Fibronectin, tenascin. Motif: RGD
MadCAM-1, CD1O6, fibronectin, Motif: (from
MadCAM-1) LDV (GLDTSL)'
E-cadherin
Vitronectin
References are: "[115]; '[ii6]; "[117]; "[118]; "[119]; '[56]; "[120] h[12i];
[122]; [123]; 5[l24] '[86, 125]; "'[126]; "[127]; "[128]; "[129]; [l30] r[13i];
S[1321 Other references can be found in [7, 133, 134, 135]. The CD
nomenclature is indicated where assigned.
o,/3, (CD49aICD29)
02/3, (CD49b/CD29)
03/3, (CD49cICD29)
a413, (CD49d/CD29)
aj3, (CD49e/CD29)
cj3, (CD49f/CD29)
07P (CD49g/CD29)
a/3, (CD49h/CD29)
09131 (CD49i/CD29)
av/3, (CD51/CD29)
a,j32 (CDI1a/CD18)
aM!32 (CDI lb/CD18)
aXf32 (CD1Ic/CD18)
00(32 (CDI1d/CD18)
a,/3 (CD41/CCD6I)
OV/33 (CD51/CD61)
0(,/34 (CD49f/CDI 04)
04137
aFt37 (CD1O3)
av13"
increased resistance of the activated 0/33 to proteolysis, consis-
tent with a change in its shape [31]. mAbs were raised that
distinguish between the active and inactive states of an integrin
[23—25]. Allostery within the extracellular domains has been
shown in electron microscopic images of integrins bound to
activating mAbs and to ligands, where the respective binding
regions are separated by a distance of 16 nm [32].
The tale of tails: Regulation of integrins through their cytoplasmic
tails
The a and /3 cytoplasmic tails of integrins play major roles in
affinity modulation [33, 34]. Deletions involving the membrane-
proximal a and /3 cytoplasmic sequences XGFFKR and LLvXi-
HDR, respectively (single letter amino acid code, X, indicating
any amino acid and small letter indicating nonconserved resi-
dues), switch integrins to a high affinity state [21, 35—38]. This
active state is independent of the cell-type, cellular metabolism or
the accompanying wild-type /3 or a cytoplasmic tails. Integrin
cytoplasmic tails also regulate post-receptor occupancy events
such as formation of focal contacts and stress fibers, which are
important for sustained adhesion. Two conserved sequences in
the /3 cytoplasmic tails (a proximal NPXYIF motif and a TTT
motif) are essential for these functions. Mutations in one or the
other of these motifs reduce cell adhesion, by impairing formation
of focal contacts and stress fibers, without affecting ligand binding
[39, 40].
The a subunit cytoplasmic tails also regulate the association of
the /3 cytoplasmic tails with cytoskeleton. Deletion of the a
cytoplasmic tail (as well as ligation of the native receptor) leads to
strong cytoskeletal associations with the /3 cytoplasmic tail, with
formation of focal contacts and stress fibers [36, 41—43]. It is likely
that the a tails allow conditional (and perhaps reversible) associ-
ation of the /3 tail with cytoskeleton. This regulatory function
allows transient forms of adhesion to take place, such as those
occurring during cell migration and rolling under flow [44], and
stable adhesion in stationary cells. It was recently proposed that
some of these effects may result from direct interaction of the a
and /3 membrane-proximal regions [38]. Several cytoskeletal pro-
teins have been shown to bind to the /3 but not a cytoplasmic tail
[34, 45]. While integrin association with the cytoskeleton is
required for stable adhesion, dissociation from the cytoskeleton
appears to be required early on to initiate adhesion. Treatment of
leukocytes with phorbol esters has been found to induce a high
affinity state in some studies [46, 47], and to increase integrin
lateral mobility in the plasma membrane, thus facilitating receptor
clustering [48]. These effects can be mimicked by low concentra-
tions of cytochalasin D (which inhibits actin polymerization). The
signaling molecules involved in regulating integrin affinity and its
complex relationship with cytoskeleton are beginning to be eluci-
dated. A novel kinase (ILKI) [49], a novel phosphatase [50] and
an adapter protein (cytohesin-1) [51] were found to interact
specifically with iritegrin cytoplasmic tails.
Life on the integrin extracellular face: Integrin-ligand
interactions
Integrin ligands: Structural diversity may be more apparent than
real
Integrins bind to diverse ligands. These include extracellular
matrix proteins, plasma proteins, cell surface proteins and micro-
bial pathogens (Table 1). Despite the diversity of their ligands,
changes. Ligand-independent changes in the spatial separation or
orientation of the exoplasmic domains of integrin alibi33 have
been revealed by fluorescence resonance energy transfer studies
following platelet activation [30]. Cell activation also led to
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Fig. 1. Schematic representation of an integrin prima,y structure. The a9 structure contains three EF-hand like motifs (dark circles in repeats 5 to 7) and
no proteolytic cleavage sites or inserted domains [1131. Other integrins contain an extra EF motif in repeat 4 (0). The a chains with inserted A-domain,
and proximal or distal cleavage sites (indicated by arrowheads) are listed. All /3 subunits have similar extracellular primary Structure containing a
conserved A-like domain and four cysteine-rich repeats (CRR). The cytoplasmic tail of /34 has four FNIII repeats and two alternative splice sites (arrows)
[1141. Extracellular ligand binding sites are indicated by asterisks.
integrins generally recognize short sequences in their ligands,
which contain a key acidic residue that is essential for receptor
binding (Table 1).
A significant advance in defining the structural requirements
for interaction of ligands with integrins have been made through
structural studies of certain ligands. The three-dimensional (3-D)
structure of three unrelated RGD-containing domains, the tenth
type-lI! fibronectin repeat from fibronectin [52] and tenascin (Fig.
2a) [53], the disintegrin Echistatin [54], and foot-and-mouth-
disease virus (FMDV) [55] revealed similar topologies of the
RGD motif. The more recent 3-D structure of the two N-terminal
immunoglobulin domains of CDIO6 (VCAM-1, a ligand for a4
integrins) [56] and of E-cadherin (a ligand for aE/37 integrin) [57,
58], also revealed an overall structural similarity (Fig. 2 b, c),
despite the lack of homology of the primary amino acid se-
quences. The RGD peptide motif in the type-Ill fibronectin
repeat is present within a conformationally mobile surface loop
connecting two /3-strands and therefore accessible for protein-
protein interaction (Fig. 2a). Similarly, the QIDSPL integrin-
binding motif of the first immunoglobulin domain of VACM-1 is
found in a surface accessible loop connecting the C and D strands
at the top of the Ig-fold (Fig. 2b). Although the integrin ligand
binding site in E-cadherin has not yet been mapped, an aspartate
residue within a conserved GAD sequence is found in its immu-
noglobulin-like CD loop in a surface-exposed region of the
structure (Fig. 2c) [57]. It therefore appears that the integrin-
binding motif requires surface accessibility as well as structural
flexibility for interaction with an integrin. In some proteins,
surface accessibility and flexibility may be intrinsic, while in
others, such as fibrinogen, they are induced following a confor-
mational change [59]. These structural studies also suggest one
mechanism for the selectivity of ligands for specific integrins. In
the group of ligands with an Ig-fold (VCAM-1, ICAMs-l to -3 and
MAdCAM-1), the length of the BC and C'E loops in domains I
and 2, respectively, vary in length, with the shortest loops found in
ICAM-1 to -3, which bind to the A-domain integrins [56]. An
additional element of specificity is provided by the regions sur-
rounding the consensus integrin-binding motifs (the CFG face in
Fig. 2b): Homologous replacement mutagenesis of the QIDS
motif with that of CD54 did not affect the selective binding of
VCAM-1 to a4/31 integrin [60].
Divalent cation binding sites in integrins
Divalent cations mediate and regulate integrin binding to the
majority of ligands [28, 61—65], and are also important for the
stability of the heterodimer in some integrins [66, 67]. The
primary structure of integrins reveals three or four EF-hand like
consensus sequences in the extracellular region of the a chains
(Fig. 1). The a133 integrin binds cations directly with an average
of 3.5 moles of metal ions/mole of receptor, suggesting that all
Fig. 2. Ribbon diagrams of the structure of some integrin ligands. (a) Structure of the third FN-IIl domain from tenascin [53]. The structure consists of
seven (3 strands arranged into two /3 sheets (ABE and C'CFG). The Arg-Gly-Asp sequence is located in the flexible FG loop that projects from the
protein surface. The homology of the FN-III fold to that of Ig (b) is apparent. (Taken from [53]. Used with permission of Science). (b) Structure of the
immunoglobulin-like domain 1 of VAM-1 (CD 106). Site-directed mutagenesis studies revealed that the integrin-binding site is comprised of residues
clustered on the CFG face, with the QIDSPL motif (Table 1) projecting from the CD loop. (Adapted from [56]. Used with permission of Nature). (c)
The overall structure of the N-terminal cadherin domain from E-cadherin [57]. The seven /3 strands (/3A through /3G) are arranged in a cylindrical barrel
and connected by two short a helices (aA and aB, shown in magenta). The strands shown in yellow appear to be involved in homotypic adhesion. An
aspartate is present in the CD loop. The Ca2 (light blue sphere) is located near the carboxy terminus and coordinated by residues from two domains.
Removal of the calcium ion abolishes adhesive activity, renders cadherins vulnerable to proteases and induces a dramatic reversible conformational
change in the entire extracellular region [58]. The cadherin fold is strikingly similar to the Ig fold (b) despite the lack of primary sequence homology.
(Adapted from [57], with permission from Science.)
Fig. 3. Schematic diagram of two fbrms of the A-domain and the metal chelation site. (a) The basic a//3 structure with alternating a helices and /3 strands
and the position of the metal (Mg or Mn) at the top of the /3 sheet are shown. The two forms are largely superimposible (grey) with the major
conformational differences shown in red for the 'open' structure (with the two phenylalanine F302 and F275 solvent exposed) and blue for the 'closed'
form (where the two phenylalanine are buried in the hydrophobic core. The strands are labeled A-F and helices 1 to 7. (b and c) Comparison of the
MIDAS motif in the 'open' and 'closed' forms, respectively. Oxygen atoms are shown in red, carbon atoms in black, and the backbone in grey, with the
glutamate from a neighboring domain in gold. Abbreviation w represents water molecules. Selected hydrogen bonds are shown as dashed red lines
(detailed in text). (Adapted from [103] with permission from Structure.)
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Fig. 4. The solvent-accessible surface of the
MIDAS face in the 'closed' and 'open'
conformations, with negatively- and positively-
charged regions shown in red and blue, respectively.
(Adapted from [1031 with permission from
"closed' "open' Stmcture.) *indicates the position of the metalion.
four EF-like motifs in the a subunit can coordinate the metal ion EF-like motifs of integrin a4 led to a significant loss in the ability
[681. The four EF-like motifs of nub (CD41) also bind cations with of a4 integrins to bind ligand [66]. Recent studies have identified
similar stoichiometry and with /LM affinity [691. Mutations in the additional divalent cation coordination sites located outside the
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EF-like regions. One such site is located within the A-domain
(Fig. 1) [651, and another in the conserved A-like domain of the (3
subunits [70].
The regulatory function of divalent cations in ligand binding
varies depending on the integrin, the ligand and the cation
involved. In general, the high affinity state of A-domain containing
integrins is facilitated by Mg2 and Mn2 and inhibited by Ca24
[28, 71]. On the other hand, Ca2 facilitates post-binding receptor
events such as receptor clustering [72]. This activity may be
important in regulating avidity and outside-in signaling events
[22]. The enhancing effects of Mn2 and Mg2 on affinity
modulation are generally applicable to the remaining integrins,
with Ca2 playing a facilitating or inhibiting function depending
on the receptor and the particular ligand [29, 731. In some
integrins, the metal ion plays an essential role in determining
specificity [73].
Ligand binding sites in the a subunits
Electron microscopy images of a11h133 integrin bound to ligand
revealed a highly specific interaction along the globular head of
the integrin, which is formed by the tvo N-terminal regions of the
a and f3 subunits [74]. Other studies utilizing biochemical, immu-
nologic and molecular biology approaches identified several Ii-
gand binding sites located in the N-terminal half of the integrin
subunits, in agreement with the morphologic studies (Fig. 1).
Given the importance of metals in integrin function, it is not
surprising that these ligand binding regions are located at or in
close proximity to the metal binding sites. Ligand binding regions
have been found within the third [751, fifth and sixth a chain
repeats, with the last two containing EF-hand like metal binding
motifs (Fig. 1) [76, 77]. Direct binding and mutagenesis studies
have identified several binding sites in the A-domain for the
physiologic ligands complement iC3b [78], ICAM-1, -2 and -3
[79—82], collagen [831, fibrinogen [84] and laminin [85], as well as
for the foreign protein neutrophil inhibitory factor (NIF; a
product of bookworms) [86] and echovirus 1 [87].
Ligand binding sites in the f3 subunits
Two ligand binding sites have also been identified in the highly
conserved A-like domain of the integrin 13 subunits (Fig. 1).
Biochemical and mutagenesis studies localized an RGD binding
site to residues 109-171 of /33 [88, 89], and a peptide (residues
118-133) from this segment was found to bind directly to the RGD
motif [90]. Point mutations in this region of 133 or 13 subunits have
defined a conserved DXSXS motif that mediates the interaction
of aIIbf3l and a5f31 with ligands [91, 92]. A second site within the
predicted A-like domain of 133 also contributes to ligand binding.
A peptide corresponding to residues 217-231 has been shown to
bind to immobilized fibrinogen, von Willebrand factor and fi-
bronectin [93], and an overlapping peptide (residues 211-222) was
shown to block fibrinogen binding [94—96]. This region, however,
may also be involved in heterodimer formation, since the peptide
211-222 binds to aJJb(33 [97], and natural mutations at R214 impair
the stability of this heterodimer [98].
Crystal structure of the ligand binding A-domain
The 3-D crystal structure of the A-domain from integrin CDI lb
has been derived at a high resolution [81 (Fig. 3). The A-domain
is an a//3 structure, composed of alternating a helices and f3
strands, with six hydrophobic beta strands arranged as a central
beta sheet surrounded by seven amphipathic helices. The N- and
C-terminal ends of the structure are adjacent to each other (Fig.
3). The a/f3 structure is adopted by many enzymes and dincu-
leotide binding proteins such as the signaling molecule ras. At the
top of the /3 sheet in the A-domain, a metal ion is coordinated by
D14OXSXS and two distal oxygenated amino acids, T209 and
D242 (Fig. 3b). Point mutations involving D140, S142, T209 or
D242 of CDllb (or their equivalents in other A-domains) abolish
binding of the domain or the intact receptor to several ligands [65,
99 —102]. The metal binding region thus appears to be required for
adhesion and this face of the structure has been named the
metal-ion-dependent-adhesion site (MIDAS). A second feature
of the structure is that the sixth metal coordination site was
donated by the carboxyl group of a glutamate residue from a
second A-domain molecule, thus forming a dimer through chela-
tion of the metal. Although this type of dimerization is likely to be
a crystal artifact, we proposed that it may be a mimic of an actual
integrin-ligand interaction, given the fact that an acidic residue is
a key component of the integrin-binding motif in ligands (Table
1). We have therefore referred to this structure as "open" or
"liganded."
Involvement of the (3 subunit DXSXS motif in ligand binding
(see above) prompted a comparison of the hydropathic properties
of the conserved region housing this motif with that of the
A-domain [8]. Although no other sequence homology is detect-
able between the a-subunit A-domain and the conserved 13-sub-
unit region using standard computer algorithms, a striking simi-
larity was apparent from hydropathy analysis, suggesting that the
ligand binding region in the integrin /3 subunits assumes a
topology similar to that of the A-domain.
A role for the A-domain in integrin affinity modulation?
The isolated A-domain from several a subunits displays similar
ligand binding profiles and metal dependency as the respective
native receptors, establishing the A domain as an independent
structural and functional unit. The isolated domain also reacts
with conformationally sensitive and insensitive mAb epitopes,
suggesting that some of the conformational changes detected
immunochemically as integrins oscillate between active and inac-
tive states occur at the level of the A-domain. Structural studies
have recently identified a second conformation of the domain
[103]. Approximately 2/3 of the structure in this form can be
superimposed on the "open" form (Fig. 3a). A major structural
difference is observed in the position of the C-terminal a7 helix,
which in the intact integrin links the structure to the rest of
membrane-spanning a subunit. The a7 helix moves up by 10 A,
repacking its hydrophobic face against the side of the domain.
This motion forces the burial of a solvent exposed residue F302 at
the top of the helix into the hydrophobic core (Fig. 3a). The burial
of F302 causes shifts in three loops and their connecting strands
and helices and a realignment of the metal chelation site in
MIDAS. A 1.5 A movement of S142 away from T209 makes it
impossible for the latter to continue to coordinate the metal
directly. Other rearrangements bury a second phenylalanine F275,
bringing D242 closer so that its side chain makes a direct bond to
the metal. The sixth metal coordination site is coordinated by a
water molecule instead of an acidic residue (Fig. 3c). This second
conformation (the 'closed' form) is therefore characterized by
direct metal coordination through D242 instead of T209, the
burial of two exposed phenylalanine and the absence of an acidic
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residue from a neighboring structure. These features are con-
served in the structure of the homologous CD1 Ia A-domain [1041.
The structural changes in the open and closed forms of the
domain exert major effects on the shape and electrostatic prop-
erties of the MIDAS face and the positions of the side chains in
relation to the metal ion (Fig. 4).
What these snapshots of the 3-D structure represent in func-
tional terms is unclear at present. First, they could be metal-driven
since the 'open' and 'closed' conformations were generated in the
presence of different cations. However, identical crystal structures
of the homologous CDI1a A-domain were obtained in the
presence of Mg2 and Mn2 [103, 105], making this possibility
less likely. A second interpretation of the structural data is that
the 'open' and 'closed' conformations represent the active an
inactive states of the domain, respectively. Indirect evidence
seems to favor this interpretation. First, the structural rearrange-
ments in metal coordination and effector region in the 'open' and
'closed' conformers bear striking resemblance to those observed
in the 'active' and 'inactive' forms, respectively, of G-protein p21
ras, a known a//3 structure. In the active (GTP-bound) ras
conformer, a Mg2 ion binds directly to a serine, a threonine and
two water molecules and indirectly to an aspartate, with the sixth
coordination site provided by the gamma phosphate oxygen of
GTP, as in the open structure (Fig. 3b). In the inactive (GDP-
bound) form, the Mg2 switches its coordination so that the bond
with threonine is lost, and a new one established with aspartate (as
in Fig. 3c). These changes lead to the burial of a hydrophobic
residue and to large changes in conformation of the effector
ligand-binding region [106-108]. Thus, the inactive conformer of
p21 ras is characterized by reduced electrophilicity of the metal
(due to direct coordination by aspartate) and burial of a hydro-
phobic residue as in the 'closed' A-domain structure, thus creating
a more thermodynamically favorable form. Second, recent evi-
dence suggest that the MIDAS face which differs significantly in
the two conformations (Fig. 4) may be a contact region for
ligands. Several mutations that impair A-domain binding to
ligands involve solvent-exposed residues on the MIDAS face [79,
109, 110], and the shape and surface charge of the MIDAS face
are dramatically altered in the absence of the metal ion, despite
minimal effects on the overall 3-D structure of the domain [1051.
The two forms of the domain probably exist in an equilibrium with
similar free energies [103], with the ligand and the cation shifting
the equilibrium to one state or the other. Interaction with
physiologic ligands may be required to stabilize the conformation
in its active state. Whether the 'open' conformation can be
generated in the absence of ligand or a ligand mimic remains to be
determined. In the whole receptor, it is likely that inside-out
signals alter the position of the flexible C-terminal a7 helix of the
domain, triggering a domino effect that changes metal coordina-
tion and the topology of the MIDAS 'effector' face, switching the
receptor to a high affinity state. Termination or modulation of the
inside-out signal may be sufficient to switch the receptor back to
the inactive form. This model can explain the inhibitory effect of
Ca2 on binding of physiologic ligands to A-domain integrins or
to the isolated A-domain [78]. The 'closed' conformation is more
likely to coordinate Ca2, since the latter prefers negatively
charged residues to the uncharged threonine residue [111]. AIlo-
steric effects can explain the reported activating and inhibitory
functions of anti-integrin mAbs [reviewed in 18], and why point
mutations in one subunit can impair ligand binding to another, a
situation quite analogous to the extensively studied hemoglobin
molecule [112]. Since all integrin /3 subunits contain a predicted
A-like domain, with ligand and metal binding activities, the above
model may also be applicable to affinity modulation in all inte-
grins. This paradigm provides a basis for understanding the
structural basis of integrin activation and a platform for investi-
gating specificity.
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